Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190446 | 1.00 | HTT (0.35) | HTTAPLNRARG1KMT2A | |
| SCHEMBL951739 | 1.00 | HTT (0.35) | HTTAPLNRARG1KMT2A | |
| Allylamine SCHEMBL27651104 | 0.85 | ARG1 (0.30) | ARG1 | |
| Allylamine SCHEMBL27651106 | 0.85 | ARG1 (0.30) | ARG1 | |
| SCHEMBL13534665 | 0.84 | — | — | |
| Valine SCHEMBL16004731 | 0.83 | SLC7A5 (0.46) | — | |
| Gamma-Aminobutyric Acid SCHEMBL1828323 | 0.82 | LMNA (0.44) | ARG1KMT2A | |
| SCHEMBL5694169 | 0.81 | HTT (0.31) | HTT | |
| SCHEMBL1770442 | 0.79 | ARG1 (0.38) | HTTAPLNRARG1KMT2A | |
| SCHEMBL6290400 | 0.79 | ARG1 (0.38) | HTTAPLNRARG1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-4455159-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| EP-4043076-B1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | GENEFRONTIER CORP (JP) | 2024-06-26 | — | — | EP | disclosed |
| US-20240092836-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | GENEFRONTIER CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| WO-2023176487-A1 | METHOD FOR PRODUCING L-PENICILLAMINE | 株式会社カネカ | 2023-09-21 | — | — | WO | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| CN-115925790-A | Methods for synthesizing alpha 4 beta 7 peptide antagonists | 领导医疗有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20030032150-A1 | Process for producing optically active (4r)-1,3-tiazolidine-4-carboxylic acid | MITSUBISHI GAS CHEMICAL CO., INC. (JP) | 2003-02-13 | — | — | US | disclosed |
| WO-2002100845-A1 | HV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| JP-2002234881-A | METHOD FOR PRODUCING OPTICALLY ACTIVE 5,5-DIMETHYL-1,3- THIAZOLIDINE-4-CRABOXYLIC ACID DERIVATIVE | NAGASE & CO LTD | 2002-08-23 | — | — | JP | disclosed |
| US-6291432-B1 | (R)-N-(2-METHYLBENZYL)-3-((2S, 3S)-3-(N-(2-CHROMONECARBONYL)-L-ASPARAGINYL)AMINO-2-HYDROXY-4-PHENYLBUTANO YL)-5,5-DIMETHYL-1,3-THIAZOLIDINE-4-CARBOXAMIDE CAN BE GIVEN AS A TYPICAL EXAMPLE OF THIS COMPOUND. | JAPAN ENERGY CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6222043-B1 | COUPLING 2-AMIDO-THIAZOLE DERIVATIVE WITH 2-PHENYL4-(PROTECTED)AMINO-BUTYRIC ACID; DEPROTECTING AMINO PROTECTING GROUP; ACYLATING PRODUCT WITH CARBOXYLIC ACID CONTAINING CARBOCYCLIC OR HETEROCYCLIC GROUP; DEPROTECTING | JAPAN ENERGY CORPORATION (JP) | 2001-04-24 | — | — | US | disclosed |
| US-6022885-A | Pyrrolidine and thiazole derivatives with antibacterial and . metallo-.beta-lactamase inhibitory properties | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-08 | — | — | US | disclosed |
| US-5962640-A | MAKING A DIPEPTIDE COMPOUND OF GIVEN FORMULA COMPRISING A ALPHA-AMINOCARBOXAMIDE INCLUDING CYCLIC GROUP LINKED TO 3-AMINO-2-HYDROXY-4-PHENYLBUTANOYL RESIDUE; HIV PROTEASE INHIBITION AND EXCELLENT BIOAVAILABILITY FROM DIGESTIVE TRACT | JAPAN ENERGY CORPORATION (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5932550-A | PROTEASE INHIBITOR; AIDS THERAPY | JAPAN ENERGY CORPORATION (JP) | 1999-08-03 | — | — | US | disclosed |
| EP-0900566-A1 | NOVEL TRIPEPTIDE COMPOUNDS AND ANTI-AIDS DRUGS | JAPAN ENERGY CORPORATION (JP) | 1999-03-10 | — | — | EP | disclosed |
| EP-0751145-A2 | HIV-protease inhibitors | Japan Energy Corporation (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | HTT 4550/4885APLNR 23/4885ARG1 617/4885 |
| US-20240092836-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | CXCL10, CXCR3, CXCR6 | HTT 3771/4885APLNR 1731/4885ARG1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.